Sorour, N., Musatafa, A., Abdel Sattar, R., Lasheen, Y. (2020). Expression of Death Receptor 3 (DR3) on Circulating CD4 Positive Lymphocytes in Patients with Alopecia Areata. Benha Journal of Applied Sciences, 5(Issue 6 part (1)), 157-160. doi: 10.21608/bjas.2020.137137
N.E. Sorour; A.I. Musatafa; R.H. Abdel Sattar; Y.F. Lasheen. "Expression of Death Receptor 3 (DR3) on Circulating CD4 Positive Lymphocytes in Patients with Alopecia Areata". Benha Journal of Applied Sciences, 5, Issue 6 part (1), 2020, 157-160. doi: 10.21608/bjas.2020.137137
Sorour, N., Musatafa, A., Abdel Sattar, R., Lasheen, Y. (2020). 'Expression of Death Receptor 3 (DR3) on Circulating CD4 Positive Lymphocytes in Patients with Alopecia Areata', Benha Journal of Applied Sciences, 5(Issue 6 part (1)), pp. 157-160. doi: 10.21608/bjas.2020.137137
Sorour, N., Musatafa, A., Abdel Sattar, R., Lasheen, Y. Expression of Death Receptor 3 (DR3) on Circulating CD4 Positive Lymphocytes in Patients with Alopecia Areata. Benha Journal of Applied Sciences, 2020; 5(Issue 6 part (1)): 157-160. doi: 10.21608/bjas.2020.137137
Expression of Death Receptor 3 (DR3) on Circulating CD4 Positive Lymphocytes in Patients with Alopecia Areata
Dermatology, Venereology and Andrology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
Abstract
Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss and preservation of the hair follicle that affect both sexes.There is scarcity in the published data that discuss the role of DR3 in pathogenesis and prognosis of AA. Therefore, our study was conducted to study this role by assessment of DR3 expression on circulating CD4 positive lymphocytes in AA patients. This study was a case control study that included 50 patients with AA in addition to 50 apparently healthy individuals of matched age and sex as a control group. Assessment of DR3 expression on circulating CD4 positive lymphocytes on both groups was done by flow cytometric analysis. Results of the present study demonstrated a significant difference in DR3 expression level between AA patients and control group. DR3 expression level was considered as risk predictor of AA occurrence. In addition, it was considered as risk predictor of active and severe (higher SALT score) cases.